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Background: Selected proton pump inhibitors (PPI) interfere with clopidogrel
metabolism, potentially attenuating P2Y12 receptor-based platelet inhibition. Previous
observational and randomized trials have reported varying results regarding the
clinical signiﬁcance of this pharmacologic interaction. We examined this relationship
in the large-scale, prospective Assessment of Dual Anti-Platelet Therapy with Drug-
Eluting Stents (ADAPT-DES) study.
Methods: Platelet reactivity testing was performed using the VerifyNow point-of-care
assay in 8,583 patients at 11 US and German sites after successful DES implantation.
All patients were treated with aspirin and clopidogrel, and were followed for 1 year.
PPI were prescribed at the discretion of treating physicians.
Results: At the time of the post-procedure P2Y12 test, 2,697 (31.4%) pts were on PPI,
and 5,886 (68.6%) were not. Major baseline characteristics, P2Y12 results and 1-year
events are summarized in the Table. The use of PPI was an independent predictor of
higher platelet reactivity (HPR) units (PRU) in a linear regression model (p<0.0001),
and additionally was independently associated with HPR as deﬁned as PRU>208 (OR
1.38 [1.25, 1.52], p¼0.0001). At discharge, 2,163 (25.2%) pts were prescribed PPI,
and 6,419 (74.8%) were not. In propensity-adjusted proportional hazards regression
models, PPI use was independently associated with out of hospital mortality (HR 1.52
[1.09, 2.12], p¼0.01) and MACE (HR 1.23 [1.00, 1.51], p¼0.049).Baseline
Characteristics PPI (n=2437) No PPI (n=6146) p-value
Mean age, years 64.4  10.7 63.3  10.8 <0.0001
Diabetes 34.8% 31.3% 0.002
Hypertension 83.7% 77.8% <0.0001
Acute coronary
syndrome
57.5% 49.0% <0.0001
VerifyNow P2Y12
Mean PRU 201.9  97.3 181.6  95.8 <0.0001
PRU > 208 49.3% 39.7% <0.0001
%inhibition 36.0  27.7 41.8  28.3 <0.0001
!-Year Follow-up
(out of hospital)
PPI
(n[2163)
No PPI
(n[6419)
Death 2.9% 1.5% <0.0001
MI 2.1% 1.7% 0.26
MACE 6.9% 5.2% 0.004
Stent thrombosis
(deﬁnite/probable)
1.1% 0.6% 0.05
Major Bleeding 5.3% 4.5% 0.11
JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: In patients treated with clopidogrel after DES, the concomitant
administration of PPI is associated with reduced platelet inhibition and adverse clinical
outcomes. Additional studies are warranted to determine the risk-beneﬁt ratio of PPI in
patients after DES.
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Background: Randomized trials have demonstrated the efﬁcacy of prasugrel vs.
clopidogrel in patients with acute MI, yet evidence of their effectiveness in real world
practice is limited.
Methods: We studied use of prasugrel vs. clopidogrel among 11,417 STEMI and
NSTEMI patients treated with PCI in the TRANSLATE-ACS study from 4/2010 to
10/2012. We used multivariable Cox models to compare 30-day MACE (death,
recurrent MI, stroke, or unplanned revascularization) and any GUSTO deﬁned
bleeding.
Results: Prasugrel was used in 2,997 MI patients (26%) during PCI. Patients treated
with prasugrel were younger (median 57 vs. 61 yrs), more likely to present with
STEMI (59% vs. 49%), and less likely to have prior MI (15% vs. 21%) or diabetes
(24% vs. 27%) than those receiving clopidogrel (p<0.01 for all). Prasugrel was used
in 57 (9%) of patients with prior stroke/TIA, 64 (5%) over age 75, and 74 (14%) of
patients <60 kg. Compared with clopidogrel, prasugrel was more often started during/
after PCI, and used with bivalirudin or GPIIb/IIIa inhibitor. Unadjusted curves for
30-day MACE and bleeding diverged, but were not signiﬁcantly different between
prasugrel and clopidogrel treated patients (Figure). Multivariable analyses did not
demonstrate signiﬁcant differences in MACE (HR 0.96, 95%CI 0.79, 1.16) and
bleeding (HR 1.04, 95%CI 0.77, 1.39).
Conclusions: While differences exist in patients receiving these drugs, the 30-day
effectiveness and safety of prasugrel vs. clopidogrel were not signiﬁcantly different in
routine practice. Long-term outcomes comparisons are necessary and ongoing.TCT-3
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Background: Prasugrel was superior to Clopidogrel in a large trial of acute coronary
syndromes patients undergoing percutaneous coronary intervention (PCI) with
heparin-based anticoagulation. It is not known whether more potent platelet inhibition
with Prasugrel rather than Clopidogrel affects infarct size and clinical outcomes when
primary PCI is performed with bivalirudin anticoagulation.acts/ORAL/Antiplatelet Agents B1
